

- ~~16.~~ The truncated MCP-2 of claim ~~15~~¹³, wherein the truncated MCP-2 has the amino acid sequence of SEQ ID NO: 5.
- ~~17.~~ The truncated MCP-2 of claim ~~15~~¹³, wherein the truncated MCP-2 lacks NH₂-terminal amino acids corresponding to amino acid residue 1 of naturally-occurring MCP-2 (SEQ ID NO: 2).
- ~~18.~~ The truncated MCP-2 of claim ~~15~~¹³, wherein the truncated MCP-2 lacks NH₂-terminal amino acids corresponding to amino acid residues 1-2 of naturally-occurring MCP-2 (SEQ ID NO: 2).
- ~~19.~~ The truncated MCP-2 of claim ~~15~~¹³, wherein the truncated MCP-2 lacks NH₂-terminal amino acids corresponding to amino acid residues 1-3 of naturally-occurring MCP-2 (SEQ ID NO: 2).
- ~~20.~~ The truncated MCP-2 of claim ~~15~~¹³, wherein the truncated MCP-2 lacks NH₂-terminal amino acids corresponding to amino acid residues 1-4 of naturally-occurring MCP-2 (SEQ ID NO: 2).
- ~~21.~~ The truncated MCP-2 of any one of claims ~~15~~ through ~~22~~²⁰, wherein the truncated MCP-2 is in glycosylated form.
- ~~22.~~ A pharmaceutical composition comprising a truncated MCP-2 of any one of claims ~~15~~ through ~~22~~²¹ and one or more pharmaceutically acceptable carriers and/or excipients.
- ~~23.~~ A pharmaceutical composition comprising a truncated MCP-2 of claim ~~25~~²¹ and one or more pharmaceutically acceptable carriers and/or excipients.